Wugen to Present Data on WU-NK-101 at the American Association for Cancer Research (AACR) Annual Meeting 2023

On March 29, 2023 Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of allogeneic cell therapies to treat a broad range of hematological and solid tumor malignancies, reported an upcoming presentation highlighting WU-NK-101, the company’s lead memory natural killer (NK) cell therapy product (Press release, Wugen, MAR 29, 2023, View Source [SID1234629505]). The data support the potential of WU-NK-101 to overcome resistance to immune checkpoint blockade (ICB) therapy and will be presented at the American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting 2023 taking place April 14 – 19, 2023 in Orlando, Florida.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of Wugen’s presentation at AACR (Free AACR Whitepaper) are as follows:

Title: WU-NK-101 as Salvage Therapy Post Immune Checkpoint Blockade (ICB)

Session: Immunotherapy Strategies and Mechanisms

Session Date and Time: Wednesday, April 19, 2023, 9:00 a.m. – 12:30 p.m. ET

Location: Section 25

Poster Number: 5

Abstract Number: 6418

Presenter: Tom Leedom

Additional meeting information can be found at View Source

About WU-NK-101

WU-NK-101 is a novel immunotherapy harnessing the power of memory natural killer (NK) cells to treat liquid and solid tumors. Memory NK cells are hyper-functional, long-lasting immune cells that exhibit enhanced anti-tumor activity and a cytokine-induced memory-like (CIML) phenotype. This rare cell population has a superior phenotype, proliferation capacity, and metabolic fitness that makes it better suited for cancer therapy than other NK cell therapies. Wugen is applying its proprietary MonetaTM platform to advance WU-NK-101 as a commercially scalable, off-the-shelf cell therapy for cancer. WU-NK-101 is currently in development for acute myelogenous leukemia (AML) and solid tumors.